Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

World psychiatry : official journal of the World Psychiatric Association (WPA)

Correll CU, Detraux J, De Lepeleire J, De Hert M.
PMID: 26043321
World Psychiatry. 2015 Jun;14(2):119-36. doi: 10.1002/wps.20204.

People with severe mental illness have a considerably shorter lifespan than the general population. This excess mortality is mainly due to physical illness. Next to mental illness-related factors, unhealthy lifestyle, and disparities in health care access and utilization, psychotropic...

Cite
Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-36doi: 10.1002/wps.20204.
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World psychiatry : official journal of the World Psychiatric Association (WPA), 14(2), 119-36. https://doi.org/10.1002/wps.20204
Correll, Christoph U, et al. "Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder." World psychiatry : official journal of the World Psychiatric Association (WPA) vol. 14,2 (2015): 119-36. doi: https://doi.org/10.1002/wps.20204
Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015 Jun;14(2):119-36. doi: 10.1002/wps.20204. PMID: 26043321; PMCID: PMC4471960.
Copy Download .nbib Format: NLM
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.

Journal of acquired immune deficiency syndromes (1999)

Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W.
PMID: 34654041
J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):191-198. doi: 10.1097/QAI.0000000000002834.

BACKGROUND: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing.SETTING: A phase 1, open-label, proof-of-concept study was...

Cite
Schürmann D, Jackson Rudd D, Schaeffer A, et al. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022;89(2):191-198doi: 10.1097/QAI.0000000000002834.
Schürmann, D., Jackson Rudd, D., Schaeffer, A., De Lepeleire, I., Friedman, E. J., Robberechts, M., Zhang, S., Liu, Y., Kandala, B., Keicher, C., Däumer, M., Hofmann, J., Grobler, J. A., Stoch, S. A., Iwamoto, M., & Ankrom, W. (2022). Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. Journal of acquired immune deficiency syndromes (1999), 89(2), 191-198. https://doi.org/10.1097/QAI.0000000000002834
Schürmann, Dirk, et al. "Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week." Journal of acquired immune deficiency syndromes (1999) vol. 89,2 (2022): 191-198. doi: https://doi.org/10.1097/QAI.0000000000002834
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):191-198. doi: 10.1097/QAI.0000000000002834. PMID: 34654041; PMCID: PMC8740605.
Copy Download .nbib Format: NLM
Mental health problems in family medicine/general practice.

International journal of family medicine

De Lepeleire J, Oud M, Buszewicz M.
PMID: 23476768
Int J Family Med. 2012;2012:794845. doi: 10.1155/2012/794845. Epub 2012 Oct 03.

No abstract available.

Cite
De Lepeleire J, Oud M, Buszewicz M. Mental health problems in family medicine/general practice. Int J Family Med. 2012;2012:794845doi: 10.1155/2012/794845.
De Lepeleire, J., Oud, M., & Buszewicz, M. (2012). Mental health problems in family medicine/general practice. International journal of family medicine, 2012794845. https://doi.org/10.1155/2012/794845
De Lepeleire, Jan, et al. "Mental health problems in family medicine/general practice." International journal of family medicine vol. 2012 (2012): 794845. doi: https://doi.org/10.1155/2012/794845
De Lepeleire J, Oud M, Buszewicz M. Mental health problems in family medicine/general practice. Int J Family Med. 2012;2012:794845. doi: 10.1155/2012/794845. Epub 2012 Oct 03. PMID: 23476768; PMCID: PMC3582092.
Copy Download .nbib Format: NLM
From .

Frontiers in plant science

Strobbe S, De Lepeleire J, Van Der Straeten D.
PMID: 30619424
Front Plant Sci. 2018 Dec 18;9:1862. doi: 10.3389/fpls.2018.01862. eCollection 2018.

Humans are highly dependent on plants to reach their dietary requirements, as plant products contribute both to energy and essential nutrients. For many decades, plant breeders have been able to gradually increase yields of several staple crops, thereby alleviating...

Cite
Strobbe S, De Lepeleire J, Van Der Straeten D. From . Front Plant Sci. 2018;9:1862doi: 10.3389/fpls.2018.01862.
Strobbe, S., De Lepeleire, J., & Van Der Straeten, D. (2018). From . Frontiers in plant science, 91862. https://doi.org/10.3389/fpls.2018.01862
Strobbe, Simon, et al. "From ." Frontiers in plant science vol. 9 (2018): 1862. doi: https://doi.org/10.3389/fpls.2018.01862
Strobbe S, De Lepeleire J, Van Der Straeten D. From . Front Plant Sci. 2018 Dec 18;9:1862. doi: 10.3389/fpls.2018.01862. eCollection 2018. PMID: 30619424; PMCID: PMC6305313.
Copy Download .nbib Format: NLM
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.

Clinical and translational science

Matthews RP, Ankrom W, Friedman E, Jackson Rudd D, Liu Y, Mogg R, Panebianco D, De Lepeleire I, Petkova M, Grobler JA, Stoch SA, Iwamoto M.
PMID: 34463432
Clin Transl Sci. 2021 Sep;14(5):1935-1944. doi: 10.1111/cts.13048. Epub 2021 Aug 31.

Islatravir (MK-8591) is a nucleoside analogue in development for the treatment and prevention of HIV-1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (Study 2) of oral...

Cite
Matthews RP, Ankrom W, Friedman E, et al. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. Clin Transl Sci. 2021;14(5):1935-1944doi: 10.1111/cts.13048.
Matthews, R. P., Ankrom, W., Friedman, E., Jackson Rudd, D., Liu, Y., Mogg, R., Panebianco, D., De Lepeleire, I., Petkova, M., Grobler, J. A., Stoch, S. A., & Iwamoto, M. (2021). Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. Clinical and translational science, 14(5), 1935-1944. https://doi.org/10.1111/cts.13048
Matthews, Randolph P, et al. "Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV." Clinical and translational science vol. 14,5 (2021): 1935-1944. doi: https://doi.org/10.1111/cts.13048
Matthews RP, Ankrom W, Friedman E, Jackson Rudd D, Liu Y, Mogg R, Panebianco D, De Lepeleire I, Petkova M, Grobler JA, Stoch SA, Iwamoto M. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV. Clin Transl Sci. 2021 Sep;14(5):1935-1944. doi: 10.1111/cts.13048. Epub 2021 Aug 31. PMID: 34463432; PMCID: PMC8504818.
Copy Download .nbib Format: NLM
Resilience in advanced cancer caregiving.

The British journal of general practice : the journal of the Royal College of General Practitioners

Opsomer S, De Lepeleire J, Lauwerier E, Pype P.
PMID: 32554635
Br J Gen Pract. 2020 Jun;70. doi: 10.3399/bjgp20X711041.

BACKGROUND: Family caregivers of advanced cancer patients are at risk for developing mental disorders. Despite this risk, the majority seem to adapt well, and throughout the caregiving period, their trajectory is characterised by healthy functioning. However, GPs struggle with...

Cite
Opsomer S, De Lepeleire J, Lauwerier E, et al. Resilience in advanced cancer caregiving. Br J Gen Pract. 2020;70doi: 10.3399/bjgp20X711041.
Opsomer, S., De Lepeleire, J., Lauwerier, E., & Pype, P. (2020). Resilience in advanced cancer caregiving. The British journal of general practice : the journal of the Royal College of General Practitioners, 70. https://doi.org/10.3399/bjgp20X711041
Opsomer, Sophie, et al. "Resilience in advanced cancer caregiving." The British journal of general practice : the journal of the Royal College of General Practitioners vol. 70 (2020). doi: https://doi.org/10.3399/bjgp20X711041
Opsomer S, De Lepeleire J, Lauwerier E, Pype P. Resilience in advanced cancer caregiving. Br J Gen Pract. 2020 Jun;70. doi: 10.3399/bjgp20X711041. PMID: 32554635.
Copy Download .nbib Format: NLM
Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week.

Journal of acquired immune deficiency syndromes (1999)

Schürmann D, Rudd DJ, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W.
PMID: 34654041
J Acquir Immune Defic Syndr. 2021 Oct 13; doi: 10.1097/QAI.0000000000002834. Epub 2021 Oct 13.

BACKGROUND: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing.SETTING: A phase 1, open-label, proof-of-concept study was...

Cite
Schürmann D, Rudd DJ, Schaeffer A, et al. Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week. J Acquir Immune Defic Syndr. 2021;doi: 10.1097/QAI.0000000000002834.
Schürmann, D., Rudd, D. J., Schaeffer, A., De Lepeleire, I., Friedman, E. J., Robberechts, M., Zhang, S., Liu, Y., Kandala, B., Keicher, C., Däumer, M., Hofmann, J., Grobler, J. A., Stoch, S. A., Iwamoto, M., & Ankrom, W. (2021). Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week. Journal of acquired immune deficiency syndromes (1999), . https://doi.org/10.1097/QAI.0000000000002834
Schürmann, Dirk, et al. "Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week." Journal of acquired immune deficiency syndromes (1999) vol. (2021). doi: https://doi.org/10.1097/QAI.0000000000002834
Schürmann D, Rudd DJ, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week. J Acquir Immune Defic Syndr. 2021 Oct 13; doi: 10.1097/QAI.0000000000002834. Epub 2021 Oct 13. PMID: 34654041.
Copy Download .nbib Format: NLM
Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital.

Therapeutic advances in psychopharmacology

Govaerts J, Boeyckens J, Lammens A, Gilis A, Bouckaert F, De Hert M, De Lepeleire J, Stubbs B, Desplenter F.
PMID: 33796267
Ther Adv Psychopharmacol. 2021 Mar 19;11:20451253211000610. doi: 10.1177/20451253211000610. eCollection 2021.

AIMS: This cross-sectional pharmacoepidemiologic study examined the prevalence of polypharmacy and psychotropic polypharmacy among inpatients in a tertiary psychiatric hospital in Belgium.METHODS: Current prescriptions of all inpatients suffering from mental disorders were extracted from the hospital Computerized Physician Order...

Cite
Govaerts J, Boeyckens J, Lammens A, et al. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital. Ther Adv Psychopharmacol. 2021;11:20451253211000610doi: 10.1177/20451253211000610.
Govaerts, J., Boeyckens, J., Lammens, A., Gilis, A., Bouckaert, F., De Hert, M., De Lepeleire, J., Stubbs, B., & Desplenter, F. (2021). Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital. Therapeutic advances in psychopharmacology, 1120451253211000610. https://doi.org/10.1177/20451253211000610
Govaerts, Jeroen, et al. "Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital." Therapeutic advances in psychopharmacology vol. 11 (2021): 20451253211000610. doi: https://doi.org/10.1177/20451253211000610
Govaerts J, Boeyckens J, Lammens A, Gilis A, Bouckaert F, De Hert M, De Lepeleire J, Stubbs B, Desplenter F. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital. Ther Adv Psychopharmacol. 2021 Mar 19;11:20451253211000610. doi: 10.1177/20451253211000610. eCollection 2021. PMID: 33796267; PMCID: PMC7985946.
Copy Download .nbib Format: NLM
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.

Journal of acquired immune deficiency syndromes (1999)

Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W.
PMID: 34654041
J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):191-198. doi: 10.1097/QAI.0000000000002834.

BACKGROUND: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing.SETTING: A phase 1, open-label, proof-of-concept study was...

Cite
Schürmann D, Jackson Rudd D, Schaeffer A, et al. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022;89(2):191-198doi: 10.1097/QAI.0000000000002834.
Schürmann, D., Jackson Rudd, D., Schaeffer, A., De Lepeleire, I., Friedman, E. J., Robberechts, M., Zhang, S., Liu, Y., Kandala, B., Keicher, C., Däumer, M., Hofmann, J., Grobler, J. A., Stoch, S. A., Iwamoto, M., & Ankrom, W. (2022). Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. Journal of acquired immune deficiency syndromes (1999), 89(2), 191-198. https://doi.org/10.1097/QAI.0000000000002834
Schürmann, Dirk, et al. "Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week." Journal of acquired immune deficiency syndromes (1999) vol. 89,2 (2022): 191-198. doi: https://doi.org/10.1097/QAI.0000000000002834
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):191-198. doi: 10.1097/QAI.0000000000002834. PMID: 34654041.
Copy Download .nbib Format: NLM
Can proxy assessments serve as a first screener for identifying people at risk for multidimensional frailty?.

European geriatric medicine

van der Vorst A, Zijlstra GAR, De Witte N, De Lepeleire J, Kempen GIJM, Schols JMGA.
PMID: 34674489
Eur Geriatr Med. 2018 Aug;9(4):501-507. doi: 10.1007/s41999-018-0067-x. Epub 2018 May 24.

PURPOSE: Timely detection of multidimensional frailty is important to prevent further negative outcomes. Perspectives of general practitioners (GPs) or informal caregivers might serve as a first, global screener to identify older people in need of a more extended assessment....

Cite
van der Vorst A, Zijlstra GAR, De Witte N, et al. Can proxy assessments serve as a first screener for identifying people at risk for multidimensional frailty?. Eur Geriatr Med. 2018;9(4):501-507doi: 10.1007/s41999-018-0067-x.
van der Vorst, A., Zijlstra, G. A. R., De Witte, N., De Lepeleire, J., Kempen, G. I. J. M., Schols, J. M. G. A. (2018). Can proxy assessments serve as a first screener for identifying people at risk for multidimensional frailty?. European geriatric medicine, 9(4), 501-507. https://doi.org/10.1007/s41999-018-0067-x
van der Vorst, Anne, et al. "Can proxy assessments serve as a first screener for identifying people at risk for multidimensional frailty?." European geriatric medicine vol. 9,4 (2018): 501-507. doi: https://doi.org/10.1007/s41999-018-0067-x
van der Vorst A, Zijlstra GAR, De Witte N, De Lepeleire J, Kempen GIJM, Schols JMGA. Can proxy assessments serve as a first screener for identifying people at risk for multidimensional frailty?. Eur Geriatr Med. 2018 Aug;9(4):501-507. doi: 10.1007/s41999-018-0067-x. Epub 2018 May 24. PMID: 34674489.
Copy Download .nbib Format: NLM
[No title available]

Tijdschrift voor gerontologie en geriatrie

De Lepeleire J.
PMID: 23203609
Tijdschr Gerontol Geriatr. 2006 Feb;37(1):3-7. doi: 10.1007/BF03074755.

No abstract available.

Cite
De Lepeleire J. Hoe functioneren ouderen? Een studie vanuit de huisartspraktijk. . Tijdschr Gerontol Geriatr. 2006;37(1):3-7doi: 10.1007/BF03074755.
De Lepeleire, J. (2006). Hoe functioneren ouderen? Een studie vanuit de huisartspraktijk. . Tijdschrift voor gerontologie en geriatrie, 37(1), 3-7. https://doi.org/10.1007/BF03074755
De Lepeleire, J. "Hoe functioneren ouderen? Een studie vanuit de huisartspraktijk." . Tijdschrift voor gerontologie en geriatrie vol. 37,1 (2006): 3-7. doi: https://doi.org/10.1007/BF03074755
De Lepeleire J. Hoe functioneren ouderen? Een studie vanuit de huisartspraktijk. . Tijdschr Gerontol Geriatr. 2006 Feb;37(1):3-7. doi: 10.1007/BF03074755. Dutch. PMID: 23203609.
Copy Download .nbib Format: NLM
Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen.

European clinical respiratory journal

Zuiker RG, Ruddy MK, Morelli N, Mogg R, Rivas VM, van Dyck K, De Lepeleire I, Tanen MR, Boot JD, Kamerling IM, Diamant Z.
PMID: 26557261
Eur Clin Respir J. 2015 May 26;2. doi: 10.3402/ecrj.v2.28319. eCollection 2015.

BACKGROUND: Allergen-induced late airway response offers important pharmacodynamic targets, including T helper 2 (TH2) biomarkers. However, detection of inflammatory markers has been limited in dithiothreitol-processed sputum.OBJECTIVES: To test whether allergen-induced TH2 inflammatory markers can be reproducibly quantified by sensitive...

Cite
Zuiker RG, Ruddy MK, Morelli N, et al. Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. Eur Clin Respir J. 2015;2doi: 10.3402/ecrj.v2.28319.
Zuiker, R. G., Ruddy, M. K., Morelli, N., Mogg, R., Rivas, V. M., van Dyck, K., De Lepeleire, I., Tanen, M. R., Boot, J. D., Kamerling, I. M., & Diamant, Z. (2015). Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. European clinical respiratory journal, 2. https://doi.org/10.3402/ecrj.v2.28319
Zuiker, Rob G J A, et al. "Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen." European clinical respiratory journal vol. 2 (2015). doi: https://doi.org/10.3402/ecrj.v2.28319
Zuiker RG, Ruddy MK, Morelli N, Mogg R, Rivas VM, van Dyck K, De Lepeleire I, Tanen MR, Boot JD, Kamerling IM, Diamant Z. Kinetics of TH2 biomarkers in sputum of asthmatics following inhaled allergen. Eur Clin Respir J. 2015 May 26;2. doi: 10.3402/ecrj.v2.28319. eCollection 2015. PMID: 26557261; PMCID: PMC4629766.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries